Naughton B A, Liu P, Naughton G K, Gordon A S
Acta Haematol. 1983;69(3):171-9. doi: 10.1159/000206884.
Recently, a factor was discovered in the serum of hepatectomized animals which was capable of augmenting the hepatic erythropoietin response to hypoxia when injected into normal rats. This substance was localized in the liver via an in situ perfusion technique and was termed the hepatic erythropoietic factor (HEF). Patients with kidney disease, liver disease, and combined renal and hepatic disease were studied in this report. Detectable HEF levels were found in the plasma of patients with both liver and kidney disease and were highest in anephric patients with various liver diseases. However, HEF levels were negligible in normal humans or in patients manifesting renal disease with no hepatic involvement. The data suggest that HEF-induced hepatic erythropoietin synthesis may occur in humans as well as in animals.
最近，在肝切除动物的血清中发现了一种因子，当将其注入正常大鼠体内时，能够增强肝脏对缺氧的促红细胞生成素反应。通过原位灌注技术将这种物质定位于肝脏，并将其命名为肝脏红细胞生成因子（HEF）。本报告对肾病、肝病以及肾肝联合疾病患者进行了研究。在患有肝肾疾病的患者血浆中发现了可检测到的HEF水平，并且在患有各种肝脏疾病的无肾患者中最高。然而，在正常人或无肝脏受累的肾病患者中，HEF水平可忽略不计。数据表明，HEF诱导的肝脏促红细胞生成素合成可能在人类和动物中均会发生。
